GLP-3R · Research Grade · ≥99% Purity
TRIPLE
RECEPTOR
AGONIST

GLP-3R simultaneously activates three metabolic receptors — GLP-1, GIP, and Glucagon — delivering synergistic effects no single-target compound can replicate. A new paradigm in metabolic research.

Request a Research Kit Explore the Science
★★★★★

Rated 4.96/5 Based on 20,000+ Reviews

Laboratory research
24%
Body Weight Change
3×
Receptor Targets
≥99%
Purity Grade
GLP-1 · GIP · Glucagon
CoA Verified · Same-Day Ship
Triple-Receptor Agonist ≥99% Chemical Purity HPLC Verified · Every Batch Certificate of Analysis Included GLP-1 + GIP + Glucagon Same-Day Shipping Available 30-Day Satisfaction Guarantee GMP-Grade Synthesis Phase 2 Clinical Reference Data Triple-Receptor Agonist ≥99% Chemical Purity HPLC Verified · Every Batch Certificate of Analysis Included GLP-1 + GIP + Glucagon Same-Day Shipping Available 30-Day Satisfaction Guarantee GMP-Grade Synthesis Phase 2 Clinical Reference Data
30
Day
Money Back
Guarantee
Our Promise

We Stand Behind Every Single Vial

PureOne Peptides is built on trust, and we aim to uphold that. If you’re not satisfied — whether the product doesn’t match its CoA, fails your independent purity test, or arrives damaged — reach out within 30 days and we will make things right. No forms, no delays, no hassle.

Research Kits

SELECT YOUR KIT

Lyophilized powder · 10mg vials · ≥99% purity · CoA included · Same-day shipping

⚠ FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
🧪
STARTER
1 Vial · 10mg GLP-3R RUO
$144
per vial
  • 1 × GLP-3R 10mg vial
  • Certificate of Analysis
  • Lyophilized powder format
  • ≥99% purity guaranteed
Select Starter Kit →
🔥 BEST VALUE · MOST POPULAR
🧬
RESEARCHER
3 Vials · Buy 2 Get 1 FREE
$287 $432
$95.67 per vial · Save $145
  • 3 × GLP-3R 10mg vials
  • 1 vial FREE — $144 value
  • Same-day shipping available
  • 30-day satisfaction guarantee
Select Researcher Bundle →
🏭
LAB SUPPLY
5 Vials · Buy 3 Get 2 FREE
$431 $720
$86.20 per vial · Save $289
  • 5 × GLP-3R 10mg vials
  • 2 vials FREE — $288 value
  • Same-day priority shipping
  • Dedicated research support line
Select Lab Supply Pack →
Mechanism of Action

TRIPLE
PATHWAY
RESEARCH

GLP-3R is the world's first compound to simultaneously engage all three major metabolic receptors. Each pathway independently produces significant research outcomes — together, they create an unprecedented synergistic effect that no combination of separate compounds can fully replicate.

Active Research Phase
GLP-1 Receptor

Appetite & Digestion Signaling

The same receptor targeted by the most-prescribed weight-loss drugs on the market. GLP-3R activates it to slow gastric emptying and reduce hunger signals directly at the brain level — the foundational mechanism of appetite research.

Research microscopy
GIP Receptor

9× Potency Fat Storage Control

Nearly nine times more potent at the GIP receptor than the body's own natural incretin signal. This controls fat storage regulation and insulin secretion at a level previously unreachable in metabolic research with a single compound.

Lab vials research
Glucagon Receptor

Direct Fat-Cell Activation

The secret weapon no other research peptide possesses. The glucagon receptor pathway directly signals adipocytes to oxidize stored energy — a mechanism completely absent in single and dual-agonist compounds. This is the true differentiator.

Cell research laboratory
Active Window

6-Day Half-Life Enables Weekly Protocols

A proprietary fatty acid chain attached to the molecule extends the active window to approximately six days. Once-weekly dosing research becomes feasible, dramatically simplifying long-duration metabolic study design and compound management.

Scientific laboratory
Laboratory research scientist
Research Applications

SIX ACTIVE
RESEARCH
PATHWAYS

GLP-3R opens research doors across six distinct biomedical disciplines — from obesity modeling to cardiovascular risk factor analysis.

⚖️
Body Weight & Fat Loss — Up to 24% body weight change over 48 weeks. Largest recorded in drug study history at that point.
🩸
Blood Sugar & Insulin Sensitivity — Dual incretin pathway activation improves glucose metabolism across research models.
🔥
Fat Oxidation Research — The glucagon pathway tells fat cells to burn directly — impossible with GLP-1 alone.
❤️
Cardiovascular Risk Factors — BP, cholesterol, and inflammatory marker research opportunities.
🫁
Hepatic Fat Research — Early data shows meaningful liver fat reduction potential.
🧠
CNS-Metabolic Crossover — Brain-level hunger signaling research beyond stomach-only mechanisms.
Compound Advantages
What sets
GLP-3R apart

Eight distinct research advantages — all from one compound. No other single peptide opens this many pathways simultaneously.

8 advantages
01
Triple-receptor synergy — GLP-1, GIP and Glucagon activated simultaneously
One molecule activates all three major metabolic receptors at once. The combined effect is stronger than any mixture of individual compounds — preclinical models confirm it outperforms every combination.
3 × 1
02
6-day half-life enables once-weekly dosing
A proprietary fatty acid chain extends the active window — dramatically simplifying long-duration study design and compound management.
Active Window
6 days
03
Preserves lean muscle while targeting fat cells
The glucagon pathway selectively signals adipocytes to oxidize energy — subjects retain lean body mass throughout, unlike broad-acting compounds.
Body Composition
Fat Only
04
Appetite suppression and fat oxidation — simultaneously
Most peptides do one or the other. GLP-3R suppresses hunger via GLP-1 and activates fat burning via glucagon — both in one clean protocol.
Dual Action
2-in-1
05
Reduces triglycerides and LDL cholesterol
Reduces ANGPTL3/8 protein via the glucagon receptor — a cardiovascular research lever completely inaccessible to single or dual-target compounds.
Cardiovascular
LDL ↓
06
Improved insulin sensitivity via dual incretin pathways
GLP-1 and GIP incretin pathways fire simultaneously — meaningful blood glucose control improvements documented across multiple research model types.
Insulin Research
GLP-1+GIP
07
Early-stage liver fat reduction signals
NAFLD is a high-priority research area. Early data shows GLP-3R can meaningfully reduce hepatic fat accumulation across preclinical models.
Liver Research
Hepatic ↓
08
Brain-level appetite signaling beyond the stomach
GLP-1 receptor activation reaches the hypothalamus directly — opening CNS-metabolic crossover research that single or dual-target peptides simply cannot access.
CNS Research
CNS+Meta
Phase 2 Clinical Trial · NEJM 2023
The data
speaks for
itself
Body weight reduction · 48 weeks · GLP-3R 12mg
−24%
Largest ever recorded in a metabolic drug trial at that point — with the curve still descending at study close.
Tirzepatide · dual receptor
−22%
2nd place comparison
Semaglutide · single receptor
−15%
Single-target baseline
338
Participants
48wk
Duration
NEJM
Published in
Ph.2
Trial phase
01
Biggest weight loss ever seen in a drug study

Up to 24% body weight reduction at 48 weeks. The largest number ever recorded in any metabolic compound trial at that point — and still descending.

Record outcome
02
Almost all weight lost was fat, not muscle

Glucagon receptor pathway selectively signals adipocytes. Lean mass preserved throughout — far more valuable than caloric restriction for body composition research.

Body composition
03
Better than three compounds given separately

Individual receptor compounds given in combination produced weaker outcomes. Simultaneous triple-binding creates irreplaceable synergy.

Synergistic effect
Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." N Engl J Med. 2023;389(6):514–526 · NCT04881760 · PubMed Indexed
Verified Researchers

WHAT LABS ARE SAYING

Real feedback from verified purchasers. Unedited, unsponsored, and independently sourced.

Lab
99%+ Purity
★★★★★

"We've been using PureOne's GLP-3R in our obesity research for months. The purity is excellent every single time — our HPLC always confirms 99%+. Consistency is remarkable."

M. Katsaris
Boston, MA
✓ Verified
Lab vials
Rapid Delivery
★★★★★

"Ordered Tuesday morning, arrived at our lab end of day. The lyophilized powder format is exactly what we need — stable, easy to reconstitute, concentration spot-on every time. PureOne is now our go-to."

T. Ramos, M.Sc.
San Diego, CA
✓ Verified
Research lab
Clean CoA
★★★★★

"Six months of ordering and every CoA shows clean results. Batch-to-batch consistency is impressive — our liver research has moved much faster thanks to a truly reliable triple-agonist compound."

S. Lindqvist
Chicago, IL
✓ Verified
Supplier Comparison
PureOne vs
the rest
Not all research peptide suppliers meet the same standard. The differences compound with every order you place.
What to look for
Our Standard
PureOne Peptides
Research Grade · RUO
Typical Market
Generic Supplier
Purity level
✓≥99% guaranteed
–~95% typical
Certificate of Analysis
✓Every single order
–Sometimes
HPLC Testing
✓Independent 3rd-party lab
–Self-reported only
Same-day shipping
✓Order by 2pm → ships today
–3–7 business days
GMP-grade synthesis
✓Full GMP standards
–Not confirmed
Batch consistency
✓Highly consistent
–Varies batch to batch
Money-back guarantee
✓30-day full refund
–None offered
Common Questions

EVERY­THING YOU NEED TO KNOW

Answers to the most common questions from research teams, lab managers, and procurement officers placing their first order.

How does it ship and how do I store it?+
GLP-3R is shipped as lyophilized (freeze-dried) powder in vacuum-sealed vials — the most stable format for research peptides. Store dry powder in a cool, dark place; for extended storage, keep at -20°C. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28–30 days. Avoid repeated freeze-thaw cycles.
How is GLP-3R different from GLP-1 compounds?+
GLP-1 compounds target a single receptor. GLP-3R activates three — GLP-1, GIP, and glucagon. The glucagon receptor is the key differentiator: it directly signals fat cells to oxidize energy, something GLP-1 compounds simply cannot do. This creates a synergy that single-receptor research cannot access.
What's included in the Certificate of Analysis?+
The CoA includes: HPLC purity percentage from independent third-party testing, mass spectrometry confirmation of molecular identity, batch number, synthesis date, storage specifications, molecular weight, and chemical formula. It's production-ready for inclusion in your research documentation.
How is purity verified?+
Every batch is independently verified to ≥99% chemical purity using HPLC (high-performance liquid chromatography) and mass spectrometry. Unlike suppliers who self-report, our testing is conducted by a third-party laboratory — and we encourage independent verification by your team.
Why lyophilized powder instead of liquid?+
Freeze-dried powder is the gold standard for research peptides — it's significantly more stable, ships safely without cold-chain requirements, and can be stored at room temperature short-term or -20°C long-term without degradation. Reconstitution with sterile bacteriostatic water produces a consistent, measurable concentration every time — critical for reproducible research.
What if I'm not satisfied with my order?+
Contact us within 30 days. If the product doesn't match its CoA, fails your independent purity analysis, or arrives damaged, we'll issue a full replacement or complete refund — your choice. We want every researcher to order with absolute confidence.
⚠️ IMPORTANT — PLEASE READ

All products sold by Pure One Peptides are FOR RESEARCH USE ONLY (RUO). They are NOT approved by the FDA for human or animal use. Not medicines. Not intended to diagnose, treat, cure, or prevent any disease. GLP-3R is for in vitro laboratory and preclinical research only. By purchasing, you confirm you are a qualified researcher and take full responsibility for compliance with all applicable laws. All clinical trial references are from published scientific literature — provided for informational context only, not as medical claims. Not for resale. Not for human or animal consumption.

Study Source: Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514–526. NCT04881760.